Introduction
Alzheimer's disease (AD) is the most common form of dementia, presently affecting more than 47 million people globally [1] . Symptoms include memory and judgement impairment, disorientation, confusion, mood swings, among others, and their management is associated with a heavy emotional and financial burden to patients, families and national health care systems [2] . With the increase in life expectancy and higher incidence of type 2 diabetes (T2D), which is nowadays generally accepted as a major risk factor for dementia, the number of AD patients is estimated to rise to more than 131 million by 2050 [1, 3] . In spite of these projections, cholinesterase inhibitors including the highly prescribed donepezil, rivastigmine and galantamine, are some of the very few drugs currently available for treating AD. What's more, in addition to a poor risk-benefit relationship [4] , these drugs are not supported by robust evidence indicating disease-modifying effects, thus placing the pursuit for new molecular entities able to interfere with the progression of AD as one of the highest priorities of health care providers worldwide.
Since 1992, the amyloid cascade hypothesis has been at the heart of the vast majority of publications concerning the pathophysiology and treatment of AD. Originally postulated by Hardy and Higgins, this hypothesis posits that the accumulation of amyloid β (Aβ) in the brain is responsible for the formation of neurofibrillary tangles, as well as the increase in intraneuronal calcium (Ca 2+ ) concentrations that ultimately result in neuronal death [4, 5] . Even though the initial focus of most AD scientists was on the dense Aβ fibril networks that constitute amyloid plaques, the past decade has led the scientific community to agree that much smaller Aβ oligomers (Aβo) are actually the most neurotoxic amyloid species of Aβ. With a spherical shape ranging from 3 nm up to 10 nm in size [6] , soluble Aβo appear to affect dielectric properties of cell membrane by bilayer insertion and domain formation, and to disrupt neuronal membrane trafficking [7, 8] . More recently, however, new evidence on the role of the cellular prion protein (PrP C ) in the molecular mechanisms underpinning the detrimental effects of Aβo in AD started to emerge. In 2009, Laurén and co-workers described PrP C as a high affinity cell-surface receptor for soluble Aβo, being able to mediate synaptic impairment caused by Aβo [9] . Accordingly, Prnp (−/−) mice (genetically engineered prion protein-deficient mice) are resistant to the neurotoxic effects of Aβo in vivo and in vitro [10] . With the subsequent discovery of Fyn kinase as a key mediator in Aβo-PrP C -induced neuronal damage [11] , it is currently believed that the Aβo-PrP C interaction triggers metabotropic glutamate receptor-5 (mGluR5)-dependent signalling events leading to the activation of Fyn kinase, with ensuing NMDA-mediated intracellular Ca 2+ influx, and activation of kinases such as glycogen synthase kinase 3β (GSK-3β) and protein tyrosine kinase 2 (Pyk2), which are ultimately involved in tau hyperphosphorylation [12, 13] . These data strongly suggest that tackling Aβo-PrP C interactions with effective protein-protein interaction inhibitors (PPIIs) might lead to new therapeutic approaches against AD progression.
Chicago sky blue, a dye used in fluorescence and immunofluorescence histochemistry, is so far the only small molecule shown to disrupt the binding between Aβ and PrP C [14] . Given the potential of Aβo-PrP C as a therapeutic target in AD, we believe that it is imperative to find new lead scaffolds with the ability to tackle the interaction between both partners, and to investigate whether molecules known to have binding affinity towards Aβ and/or exert neuroprotective effects could, in fact, act by disrupting Aβo-PrP C interactions. In this perspective, we followed a line of investigation that started with the recognition of chrysin (Fig. 1a) as a suitable prototype structure for the interaction with Aβ and inhibition of small Aβo formation [15] . We were furthermore interested in finding out if the insertion of a C-glucosyl moiety could somehow optimize the activity of chrysin derivatives, since vitexin ( Fig. 1a ) and other glycosyl flavones had been described to exert neuroprotective effects against Aβ-induced toxicity in vitro [16, 17] . Hence, we directed our research efforts to the design and synthesis of a primary series of flavones and corresponding C-glucosyl derivatives, from which our preliminary screening tests selected both morpholinyl derivatives 1 and 2 (Fig. 1b) as the most promising neuroprotective agents against Aβ 1-42 -induced toxicity in SHSY-5Y human neuroblastoma cells, with the ability to restore cell viability at 50 μM (unpublished data).
The present work focuses on the chemical modifications introduced in the lead compounds 1 and 2 that resulted in the discovery of new molecules able to disrupt Aβo-PrP C interactions. Figure 2 summarizes our strategy for the design and synthesis of a small library of C-glucosyl flavone derivatives and their corresponding aglycones, which included a series of bioisosteric replacements of ring D, as well as the insertion of halogen atoms in ring B, among other alterations. Our main goal was to explore the potential of these compounds by STD NMR in order to evaluate their binding affinity towards Aβo, while developing a brief structure-activity relationship study. We subsequently present a functional assay aimed at exploring if some of the most relevant interactions with Aβo could translate into the highest potential to disrupt Aβo-PrP C interactions.
Chemistry
The synthetic route for C-glucosyl flavone derivatives started with a TMSOTf-promoted reaction between glycosyl donor 3 and 2,4,6-trihydroxyacetophenone 4, to give intermediate 5 (Scheme 1). Then, after selective benzylation of two hydroxy groups, chalcone intermediates 7-20 were generated in base-catalysed ClaisenSchmidt aldol condensation reactions under high temperature of compound 6 with different aldehydes. In order to engage in an efficient and highly systematized synthetic process, only commercially available aldehydes or their N-Boc protected derivatives were chosen to be used in this step. Lastly, the chalcones were cyclized in the presence of iodine and pyridine, after which all protecting groups were removed using BBr 3 at −78 °C to give the final compounds 1 and 21-32.
As for the non-glycosylated flavones, 2,4,6-trihydroxyacetophenone (4) was selectively protected with ethoxymethyl ether groups (EOM) in a K 2 CO 3 -promoted reaction to afford compound 33 (Scheme 2). Then, in the presence of each aldehyde, chalcone intermediates 34-46 were generated following the same procedure described for the synthesis of C-glucosyl chalcones; however due to the use of smaller protecting groups and absence of the sugar moiety, these reactions proceeded efficiently at room temperature. Finally, each chalcone went through the oxidative cyclization reaction in the presence of iodine and pyridine, followed by deprotection using catalytic amounts of p-toluenesulfonic acid (p-TSOH) and acetic acid (AcOH) in ethanol under reflux, to give the final compounds 2 and 47-57.
Notably, compounds 14 and 46 bearing the morpholine group in ortho position of ring B, did not afford the corresponding flavones due to chemical instability of the protected intermediates and/or the final compound. Reaction yields of all compounds are provided in Table 1 between rings B and D succeeded at further recovering interaction points with Aβo in both rings A and B, with STD-NMR signals corresponding to protons H-3 and H-6 being unambiguously detected in the difference spectrum, at 6.70 ppm and 6.11 ppm, respectively. From all the halogen-containing C-glucosyl flavone derivatives, compound 29 was the only analogue presenting a satisfactory binding interaction with Aβo by STD NMR. STD signals matching protons H-6′ and H-3′ in ring B, as well as protons H-3 and H-6 in rings C and A, respectively, are clearly visible. We propose that the difference in bulkiness between the halogens in compounds 28 and 29 might be the underpinning reason for this result, as the larger size of the bromine atom might trigger alterations in the conformation and/or spatial orientation of the morpholine moiety, leading to a more suitable overall conformation of the flavone core. Yet, the introduction of the halogen did not match the full effect of the thiomorpholinyl detivative 22, as the STD NMR signal for the anomeric proton H-1″ failed to be observed in its difference spectrum.
Contrarily to the C-glucosyl flavones, aglycones generally displayed relevant water solubility issues. For this reason, the solvent pH had to be increased until signal-to-noise ratio was satisfactory in the reference spectra. However, none of the aglycones succeeded in presenting any signs of interaction with Aβo by STD NMR, with the exception of compound 51 (Fig. 4) . The design of both compounds 26 and 51 was based on the introduction of a CH 2 bridge between rings B and D to increase molecular flexibility by allowing ring D to rotate around the new C-N bond. Indeed, compound 51 (Fig. 4b) was the only one amongst the synthesized set of aglycones to present good water solubility, despite the highly lipophilic flavone core. It was also the only aglycone presenting any STD interactions with Aβo and, overall, one of the most promising molecules of this study. Figure 4a shows that the binding mode of compound 51 towards Aβo unequivocally involves both aromatic protons of ring A (H-6 and H-8, at 6.10 ppm and 6.37 ppm), all aromatic protons of ring B (H-2′, H-3′, H-5′ and H-6′, at 7.45 ppm and 7.91 ppm), as well as the olefinic proton in ring C, H-3 (at 6.63 ppm). With a much lower signal-to-noise ratio, small peaks that could correspond to the protons of the piperazine moiety appear at 2.16 ppm and 1.85 ppm; however, due to the background spectrum (see Supporting Information, Fig. S2) , it is not possible to correctly assign the exact origin of these signals. All in all, the comparison between the signal-to-noise (SNR) relative intensity of the binding epitope points towards H-3 as the most relevant point of interaction between compound 51 and the target amyloid aggregates, followed by both protons in ring A, H-6 and H-8 (Fig. 4c) . Although significant, the interaction between ring B and Aβo does not appear to contribute as much to the binding epitope of this molecule.
The Central Nervous System (CNS)-MultiParameter Optimization (MPO) algorithm is a published mathematical tool that enables the alignment of six key drug-like attributes (partition coefficient, distribution coefficient, pKa, molecular weight, topological polar surface area and the number of hydrogen bond donors), by providing an estimation of a given small molecule to enter the central nervous system, while displaying (REF) and difference (DIFF) spectra, compounds were added in DMSO to a 2 μM solution of freshly prepared Aβo in a mixture of deutered phosphate buffer (pH 7.4) and neurobasal medium, to achieve a final compound concentration of 200 μM (1:100 molar ratio). Control (CTRL) experiments were carried out in the same conditions, but in the absence of Aβo.
favourable permeability, P-gp efflux, metabolic stability and safety [20] . From a scale of 0-6, compound 51 exhibited a CNS-MPO desirability score of 4.9, which is highly preferable to the 2.5-3.6 scores exhibited by C-glucosyl flavones, at least in view of mere passive diffusion processes. Based on these data, and given that compound 51 was the only water soluble aglycone in this study with proven ability to bind to the target amyloid aggregates, we decided to further explore the potential of our N-methylpiperazinyl flavones in this study, particularly focusing on compound 51.
We thus conducted an STD NMR competition experiment between analogue 51 and the high-affinity Aβ ligand bexarotene, in order to assess if any of these two compounds could act as an enhancer or inhibitor of each other's binding affinity towards Aβo. Moreover, based on some level of structure similarity between them, we were also interested in investigating whether they would bind to the same or different binding sites in the target protein. Figure 5 shows that bexarotene displaced compound 51 from binding to Aβo, with only a very small STD signal corresponding to H-6 of 51 appearing in the difference spectrum. While these data indicate that bexarotene ought to have a higher binding affinity towards the target, they also show that compound 51 possibly interacts with Aβo at the same binding site as bexarotene. This compound binds to a linear motif at the C-terminal of Aβ peptide, in a region encompassing residues 22-35, being therefore able not only to inhibit cholesterol-induced oligomerization of Aβ 1-42 into calcium-permeable ion channels formed by Aβ in the neuronal lipid membrane, but also to counteract the disruption of actin cytoskeleton induced by Aβo [21, 22] . If 51 and bexarotene are both able to bind to the same binding site(s) in Aβo, it is plausible that 51 and structurally-related compounds might also have an impact in these mechanisms that contribute to the neurodegenerative process in AD. 
Assessment of Aβo-PrP C interaction disruption by flavones
The next step in this investigation was to assess if the STD NMR results obtained for compound 51 and related N-methylpiperazinyl flavones could translate into a positive outcome in a functional assay. Hence, we tested this small set of molecules on their ability to disrupt Aβo-PrP C interactions in human embryonic kidney (HEK) cells, in which PrP C is endogenously expressed. From all tested compounds, C-glucosyl flavone analogue 26 exhibited the highest potential do disrupt Aβo-PrP C interactions (Fig. 6a) , presenting an inhibition percentage of 41 % at 10 μM, with high statistical significance when compared to Aβo-PrP C control (P-value < 0.001). As displayed in Fig. 6a , this compound shows a significantly better prognosis for further development when compared to its aglycone, compound 51: in fact, contrarily to our initial expectation, the higher number of interaction points with Aβo in the STD NMR screening experiment did not necessarily translate into the highest interaction-disrupting potential (a similar result was obtained for the bromine-containing C-glucosyl derivative 29, with just 26 % of Aβo-PrP C binding inhibition percentage; see Supporting Information, Fig. S3 ). These results seem to indicate: (1) that compound 51 has greater binding affinity for Aβo in a region that is not involved in Aβo-PrP C interaction; and (2) that compounds 26 and 50, which displayed only moderate or low affinity towards Aβo by STD NMR, are nonetheless able to bind to the Aβo-PrP C interaction surface, thus competing with Aβo for binding towards PrP C . Moreover, in the case of the pair of compounds 26/51, the sugar moiety was clearly able to tune the activity of the aglycone towards a more specific interaction between the compound and the complex Aβo-PrP C . What's more, Fig. 6b shows that the effect of 26 is dose-dependent, with statistical significance achieved from 10 μM to 20 μM of compound when compared to the Aβo-PrP C control. In a MTT assay performed in the same cell line, none of the four N-methylpiperazinyl flavones exhibited relevant signs of cytotoxicity at 20 μM, with average cell survival rates above 77 % in all cases. However, cells treated with 50 μM of aglycones 50 and 51 only displayed 56 % ± 3 % and 36 % ± 6 % of cell viability, respectively, whereas their C-glycosides displayed 91 % ± 4 % and 79 % ± 1 %, in turn. These results indicate that C-glycosylation could be viewed as a valuable tool for reducing the cytotoxicity of flavones as well. Anyhow, all four N-methylpiperazinyl flavone derivatives 25-26 and 50-51 presented statistically significant differences in the number of Aβo-PrP C units when compared to the non-treated control ( Fig. 6a) and, thus, the use of these types of compounds as blockers of Aβo-PrP C interactions should ultimately be regarded as a novel strategy against neuronal damage in Alzheimer's disease, with potential for further development and optimization.
Conclusions
In this work, we presented the synthesis of 24 novel C-glucosyl flavones and aglycones with therapeutic potential against AD. Based on the existing robust evidence pointing towards Aβo-PrP C complexes as valuable therapeutic targets for the development of PPIIs with neuroprotective activity, our goal was to study the synthesized compounds as Aβo-binders, and to assess whether the best molecules would also behave as promising Aβo-PrP C interaction blockers. C-glucosyl derivatives displayed optimal water solubility and were generally able to interact with Aβo by STD NMR. On the other hand, compound 51 stood out from the set of non-glycosylated derivatives for being the only water-soluble aglycone, and the only one to exhibit the ability to interact with the target amyloid aggregates. Indeed, the presence of the (4-methylpiperazin-1-yl)methyl moiety in this flavone derivative results in higher molecular flexibility when compared to its planar analogues, and allows free rotation of the N-methylpiperazinyl group around ring B without compromising brain penetrance estimations by passive diffusion. Ultimately, this feature successfully promoted the establishment of interactions between compound 51 and Aβo mediated by the whole flavone core. Our results additionally indicate that compound 51 competes with the bexarotene for the same binding site(s) in Aβo. To this point, mostly due to the low stability and high size variability of Aβo, it is not clear exactly where bexarotene binds in these small amyloid aggregates; nevertheless, our data suggest that compound 51 and related analogues might have the potential to yield similar effects by interfering with damaging events directly induced by Aβo, such as the disruption of the actin cytoskeleton in neurons [21] .
A cell-based functional assay in HEK cells revealed that all four N-methylpiperazinyl flavone derivatives were able to significantly disrupt the binding between Aβo and PrP C at 10 μM. Compound 26, the C-glucosyl Results are presented as means ± standard deviation of two experiments preformed in triplicates. Statistical differences between groups were assessed by one-way ANOVA followed by a Tukey's post-test. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Aβo-PrP C control; § P < 0.05 vs. another compound.
derivative of 51, presented the highest ability to block Aβo-PrP C interactions in a dose-dependent manner, with 41 % of inhibition capacity at 10 μM. Interestingly, significant differences were observed when comparing its activity to that of its aglycone, indicating that, in this particular case, the sugar moiety was able to optimize the affinity of aglycone 51 towards the Aβo-PrP C interaction region, possibly being itself part of the binding epitope. Even though sugars are not the best candidate scaffolds for crossing the blood-brain barrier by passive diffusion due to their physicochemical properties, previous evidence has recognized sugar conjugates as molecules with adequate brain-penetrating capacity (in some cases improved when compared to their aglycones) [23, 24] . In fact, it is thought that the sugar moiety might behave as a shuttle and induce the passage of the compound into the CNS due to its high affinity towards glucose transporter 1 (GLUT-1) located in the blood-brain barrier (BBB), even though the transport can occur in both directions (in and out of the brain). Examples include the C-glucosyl flavone spinosin, and anthocyanin glycosides, among others [25] [26] [27] . Ultimately, we show, for the first time in this work, the potential of non-toxic N-methylpiperazinyl flavones and their sugar conjugates as Aβo-PrP C interaction disruptors, thus opening a new line of investigation towards the discovery of new drug candidates with neuroprotective potential against AD progression.
Experimental section Chemistry
HPLC grade solvents and reagents were obtained from commercial suppliers and were used without further purification. Chrysin was purchased from Sigma Aldrich. LCMS experiments were performed in a column XBridge C18 3.5u 2.1 × 50 mm at 1.2 mL/min and 50 °C; 10 mM ammonium bicarbonate pH 9/ACN, gradient 10 > 95 % ACN in 1.5 min + 0.5 min hold. Flash column chromatography was performed using CombiFlash ® Rf200 (Teledyne Isco). Preparative HPLC was performed in a Gilson apparatus using either Phenomenex gemini NX, C18, 5 μm 30 × 100 mm or Phenomenex gemini NX, C18, 10 μm 50 × 150 mm columns. NMR spectra for compound characterization were recorded on a Bruker AV III HD Nanobay spectrometer running at 400.13 MHz equipped with a room temperature 5 mm BBO Smartprobe with Z-gradients capable of 19 F observation. Chemical shifts are expressed in δ (ppm) and the proton coupling constants J in hertz (Hz). NMR data were assigned using appropriate COSY, DEPT, HMQC, and HMBC spectra. For the characterization of chalcones, protons and carbons in ring A (aromatic ring attached to the carbonyl group) are assigned as H′, C′; in ring B (aromatic ring attached to the propenone double bond) as H″, C″; and those belonging to the glucosyl moiety as H‴, C‴, while propanone atoms are labeled from 1 to 3, to facilitate the description of compound chemical shifts. Melting points were measured with a SMP3 melting point apparatus, Stuart Scientific, Bibby Melting points were obtained with a SMP3 Melting Point Apparatus, Stuart Scientific, Bibby (r.t. < m.p. < 360 °C). Optical rotations were measured with a Perkin-Elmer 343. High resolution mass spectra of new compounds were acquired on a Bruker Daltonics HR QqTOF Impact II mass spectrometer (Billerica, MA, USA). The nebulizer gas (N 2 ) pressure was set to 1.4 bar, and the drying gas (N 2 ) flow rate was set to 4.0 L/min at a temperature of 200 °C. The capillary voltage was set to 4500 V and the charging voltage was set to 2000 V. Tested compounds have ≥95 % purity as determined by LCMS.
Synthesis and characterization of compounds 5 and 6 were carried out according to the previously reported procedures [28] .
General procedure for the synthesis of benzyl-protected C-glucosyl chalcones
Compound 6 was dissolved in 1,4-dioxane (0.667 mmol in 8 mL) and the appropriate benzaldehyde (0.734 mmol, 1.1 eq.) was added. The mixture was stirred until fully homogenized. Then, an aqueous solution of NaOH 50 % (w/v, 8 mL) was slowly added and the mixture was stirred under reflux for 18 h-24 h. All reactions were followed by LCMS. Once the starting material was fully consumed, the mixture was allowed to reach room temperature. The reaction was quenched using HCl 2 M, washed with brine and extracted with EtOAc (3 × 15 mL). The organic layers were combined, dried over MgSO 4 , filtered and concentrated under vacuum. The residue was purified using the most adequate purification method(s) to afford compounds 7-20. 1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl) 
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[4-(4-methylpiperazin-1-yl)phenyl]prop-2-en-1-one (12):
Purified by precipitation in cold methanol, followed by filtration under reduced pressure. 1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[3-(morpholin-4-yl) 
(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[2-(morpholin-4-yl)phenyl]prop-2-en-1-one (18):

(2E)-1-[4,6-dibenzyloxy-2-hydroxy-3-(2,3,4,6-tetra-O-benzyl-β-d-glucopyranosyl)]phenyl-3-[(4-dimethylamino)phenyl]prop-2-en-1-one (19):
General procedure for the synthesis of C-glucosyl flavones
Each C-glucosyl chalcone 7-20 was dissolved in dry pyridine (0.172 mmol in 5.11 mL). Then, catalytic amounts of I 2 (0.060 mmol, 0.35 eq.) were added and the mixture was stirred under reflux for 48 h-72 h. All reactions were followed by LCMS. Once the starting material was fully consumed, the mixture was allowed to reach room temperature and the pyridine was co-evaporated with toluene under reduced pressure. The residue was resuspended in dichloromethane, washed first with a saturated solution of sodium thiosulfate, and then with brine. The flavone was extracted with dichloromethane (3 × 30 mL), dried over MgSO 4 , and the solution filtered and concentrated under vacuum. The residue was then resuspended in extra dry dichloromethane (7.10 mL) and stirred at −78 °C under N 2 saturated atmosphere. A 1 M solution of BBr 3 in dichloromethane (1.72 mmol, 10 eq.) was added in a dropwise manner over 5 min, and the reaction stirred for 2 h-4 h. After having reached completion by LCMS, the reaction was quenched with a 1:1 mixture of dichloromethane/ methanol (ca. 15 mL) and the reaction was stirred for approximately 20 min at room temperature. The solvent was evaporated under vacuum and the residue purified using the most adequate purification method(s) to afford compounds 1 and 21-32. 79 (m, 1H, H-6″a), 3.55-3.50 (m, 1H, H-6″b), 3.41-3.22 (m, 7H, H-3″ 1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]ethan-1-one (33): 2,4,6 -trihydroxyacetophenone (4, 3 g, 16.12 mmol) was dissolved in dry acetone (60 mL), after which anhydrous potassium carbonate (4.90 g, 35.45 mmol, 2.2 eq.) was added at room temperature. The mixture was stirred at room temperature for 5 min, and then methyl ethoxymethyl chloride (EOMCl, 3.30 mL, 2.2 eq.) was added in a dropwise manner. The mixture was stirred under reflux for the next 4 h and followed by LCMS. After complete disappearance of the starting material (91 % reaction yield), the reaction mixture was allowed to cool down to room temperature and the solvent was evaporated. Then, the residue was resuspended in EtOAc, washed with brine and extracted with EtOAc (3 × 50 mL). The organic layers were combined, dried over MgSO 4 
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(morpholin-4-yl
5,7-Dihydroxy-8-(β-d-glucopyranosyl)flavone (21):
5,7-Dihydroxy-8-(β-d-glucopyranosyl)-4′-(piperidin-1-yl)flavone (23): Purified by preparative HPLC followed by SFCMS (naphthyl column
Synthesis of
General procedure for the synthesis of non-glycosylated EOM-protected chalcones
Compound 33 was dissolved in 1,4-dioxane (1.055 mmol in 4 mL) and the appropriate benzaldehyde (1.583 mmol, 1.5 eq.) was added. The mixture was stirred until fully homogenized. Then, an aqueous solution of NaOH 50 % (w/v, 4 mL) was slowly added and the mixture was stirred at room temperature for 3 h-24 h. All reactions were followed by LCMS; once the starting material was fully consumed, the reaction was quenched using HCl 2 M, washed with brine and extracted with EtOAc (3 × 10 mL). The organic layers were combined, dried over MgSO 4 , filtered and concentrated under vacuum. The residue was purified using the most adequate purification method(s) to afford compounds 34-46. 1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[4-(piperidine-1-yl) (2E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxy]phenyl-3-[2-fluoro-4-(morpholin-4-yl) C-3′) 
STD NMR screening assay against Aβo
All samples were prepared in 550 μL of deutered 10 mM phosphate buffer. Aβo and test compounds were added to reach final concentrations of 2 and 200 μM, respectively (1:100 molar ratio). The final percentage of DMSO was 2 % in screening experiments, and 4 % in the competition assay between compound 51 and bexarotene. Controls were prepared in the absence of Aβo, but maintaining the same relative volumes of buffer, Neurobasal Medium and DMSO. All experiments were performed on a Bruker Avance III or 600 MHz spectrometer equipped with a QCI cryoprobe. For the acquisition, a standard Bruker pulse sequence was used, with 2 s of saturation at 0 ppm and −40 ppm for on and off resonance. Double solvent suppression was achieved with a DPFGSE element incorporating a selective 180 pulse designed to flip both the water (from buffer) and DMSO (from ligand stock) peaks. Typically, 128 scans were acquired prior to processing with a 1 Hz lien broadening function. Data were processed in topspin using the stdsplit AU program.
Cell culture
Human embryonic kidney (HEK) cells were grown in Dulbecco's modified essential medium (DMEM; D5796, Sigma) supplemented with 10 % fetal bovine serum (FBS; 10695023, Fisher), 1 % penicillin-streptomycin (10452882, Fisher) and 4 mM L-glutamine (G7513, Sigma), and maintained at 37 °C in a 5 % CO 2 atmosphere.
Immunocytochemistry analysis of compound-mediated Aβo-PrP C disruption
Ninety six-well plates were incubated with 50 μL of poly-l-ornithine hydrobromide 100 μg/mL for 40 min and washed with PBS 3 times. HEK cells were seeded onto the plates diluted in Phenol red-free DMEM medium with high glucose (Gibco) to achieve 2 × 10 4 cells per 100 μL in each well. The cells were incubated at 37 °C with 5 % CO 2 overnight. Then, the medium was removed and 50 μL of conditioning medium with recombinant Aβo prepared by the Sheffield Institute for Translational Neuroscience (SiTraN) 1000 pc/mL was added to each well. These oligomers were derived from Chinese Hamster Ovary cells (7PA2 cells) stably transfected with cDNA encoding APP751, an amyloid precursor protein that contains the Val717Phe familial Alzheimer's disease mutation, as previously described by Kittelberger et al. [31] . After a 2 h-long incubation period, the conditioning medium was removed and the cells were washed once with PBS. Then, 100 μL of fresh Phenol red-free DMEM medium with high glucose were added to each well and the cells were incubated with the flavone derivatives at the desired concentration (10 μM in the screening assay or 1 μM-20 μM in the doseresponse experiment with compound 26) in 0.5 % of DMSO for 1 h. The medium was subsequently removed. The cells were washed with 100 μL of PBS containing Mg 2+ and Ca
2+
, after which 100 μL of 4 % PFA were added to each well. Once incubated for 15 min at room temperature, the PFA was removed and the cells were washed once again with 100 μL of PBS containing Mg 2+ and Ca
. One hundred μL of PBS-T with 5 % of Donkey serum were added and the cells were incubated for 1 h at room temperature. Then, the blocking solution was removed and the primary antibody (anti-Aβo 6E10 antibody prepared in 50 μL of PBS-T with 5 % of Donkey serum, 1:250 dilution) was added prior to overnight incubation at 4 °C. After removal of the primary antibody, the cells were washed 3 times with 50 μL of PBS-T for 5 min at room temperature. Fifty microliter of the secondary antibody (Alexa fluor 594 anti-mouse antibody, prepared in PBS-T, 1:500 dilution) were subsequently added to each well and the cells were incubated another hour at room temperature. The liquid was aspirated and the cells were washed twice with PBS-T and once with PBS (50 μL each wash). Fifty microliter of 4′,6-diamidino-2-phenylindole (DAPI, 100 ng/mL in PBS) were added to each well. Following 5 min of incubation, DAPI was removed and the cells washed with 100 μL of PBS 3 times. One hundred microliter of PBS were finally added and the imaging was carried out by The Wolfson Light Microscopy Facility, using ImageXpress Micro Widefield High Content Screening System, 20 × magnification, and 30 pictures taken per each well.
